- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01573429
Bisphenol A Controlled Exposure Study
Bisphenol A (BPA) Pharmacokinetic (PK): Controlled Exposure Study
Background:
- Bisphenol A (BPA) is a chemical that is used primarily to make plastics, resins, and thermal paper. Most people are exposed daily to low levels of BPA that leaches into food and water from plastic products, including water and baby bottles. However, not all of the risks of BPA are known. Researchers want to learn more about how BPA acts in the body, and how the body gets rid of BPA.
Objectives:
- To study controlled exposure to BPA and its effects on the body.
Eligibility:
- Healthy, non-obese volunteers between 25 and 45 years of age.
Design:
- Participants will have six visits over about 2 to 4 weeks for this study.
- At the first visit, participants will be screened with a physical exam and blood and urine tests. They will complete a questionnaire about exposure to BPA-containing products. They will also receive a list of medications that should not be taken during the study period.
- The second visit will last about 13 hours. Participants will fast for 8 hours before the visit. They will then have a single dose of d-BPA (a modified form of BPA that is easier to study in the body). Regular blood samples will be taken over the 13-hour visit. All urine will also be collected. Participants will receive breakfast and lunch during the visit.
- Participants will have four follow-up visits. They will collect and store all of their urine between each follow-up visit. Blood samples will be collected at the follow-up visits....
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Research Triangle Park, North Carolina, United States
- NIEHS Clinical Research Unit (CRU)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Participants meeting all of the following criteria will be considered for admission into this study:
- Male or female 25-45 years of age at the time of enrollment.
- Able to fast overnight (at least 8 hours).
- Able to understand and provide written informed consent in English.
- Able to travel to the NIEHS Clinical Research Unit (CRU) for all required study visits.
- Male and females of reproductive age agree to use contraception to avoid conceiving a child and agree not to donate eggs or sperm for six months following their participation in the study.
EXCLUSION CRITERIA:
Uncontrolled diabetes:
--Hemoglobin A1C of greater than or equal to 6.5% or a fasting blood glucose of greater than or equal to 126 mg/dL.
Known liver dysfunction or disease:
- ALT - higher than the normative value or determined abnormal by the PI.
- AST - higher than the normative value or determined abnormal by the PI.
- ALP - higher than the normative value or determined abnormal by the PI.
Known kidney dysfunction or disease:
- Estimated Glomerular Filtration Rate (eGFR)- <60 ml/min per the MDRD equation.
- Clinically relevant anemia as defined as hemoglobin concentration <13g/dL for males and hemoglobin concentration <11g/dL for females.
- Pregnancy: Positive serum quantitative hCG pregnancy test.
- Current lactation.
- BMI less than or equal to 19 and greater than or equal to 35
- Medication use: Given the widespread use of medications, it may not be practical to instruct subjects to avoid all medication prior to and during the study. Thus, participant exclusion will be based on use of medications within 48 hours of the exposure and for the 6 days following the exposure that affect glucuronidation of the d-BPA dosage: Salicylic acid, acetaminophen, ibuprofen, naproxen, mefenamic acid, diclofenac, gliclazide carbamazepine, valproic acid, cimetidine, sulfasalazine, amoxicillin and erythromycin.
- Recent blood donation within the past 8 weeks of the BPA exposure visit (so as not to exceed donation of 10.5 mL/kg or 550 mL over an 8 week period).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Dermal Carboxymethylcellulose arm
d-BPA administered dermally using a carboxymethylcellulose suspension
|
The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
|
Other: Dermal ethanol arm
d-BPA is administered dermally using an ethanol solution
|
The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
|
Other: Oral arm
d-BPA administered orally
|
The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of d-BPA and d-BPA conjugates in blood and urine over 6 days
Time Frame: 6 days
|
The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or acarboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
|
6 days
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 120089
- 12-E-0089
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on deuterated-Bisphenol A (d-BPA)
-
Sanliurfa Mehmet Akif Inan Education and Research...Bursa Yüksek İhtisas Education and Research HospitalCompletedNeural Tube Defects | Bisphenol-ATurkey
-
California Polytechnic State University-San Luis...American Diabetes AssociationUnknownGlucose Metabolism Disorders | Insulin Sensitivity | MicrotiaUnited States
-
The University of Texas Medical Branch, GalvestonCompletedCachexiaUnited States
-
Aljazeera HospitalCairo University; Kasr El Aini HospitalCompleted
-
Université de MontréalUnknown
-
Coopervision, Inc.Completed
-
NYU Langone HealthCompletedPhthalate Exposure | Bisphenol ExposureUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.; Singapore Polytechnic UniversityCompleted
-
GlaxoSmithKlineCompletedMultiple Sclerosis, Relapsing-RemittingAustralia